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Abstract
Aim: Maintenance of the blood and extracellular volume requires tight con-
trol of endothelial macromolecule permeability, which is regulated by cAMP
signalling. This study probes the role of the cAMP mediators rap guanine
nucleotide exchange factor 3 and 4 (Epac1 and Epac2) for in vivo control of
microvascular macromolecule permeability under basal conditions.
Methods: Epac1/ and Epac2/ C57BL/6J mice were produced and
compared with wild-type mice for transvascular flux of radio-labelled
albumin in skin, adipose tissue, intestine, heart and skeletal muscle. The
transvascular leakage was also studied by dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) using the MRI contrast agent
Gadomer-17 as probe.
Results: Epac1/ mice had constitutively increased transvascular macro-
molecule transport, indicating Epac1-dependent restriction of baseline per-
meability. In addition, Epac1/ mice showed little or no enhancement of
vascular permeability in response to atrial natriuretic peptide (ANP),
whether probed with labelled albumin or Gadomer-17. Epac2/ and
wild-type mice had similar basal and ANP-stimulated clearances.
Ultrastructure analysis revealed that Epac1/ microvascular interendothe-
lial junctions had constitutively less junctional complex.
Conclusion: Epac1 exerts a tonic inhibition of in vivo basal microvascular
permeability. The loss of this tonic action increases baseline permeability,
presumably by reducing the interendothelial permeability resistance. Part
of the action of ANP to increase permeability in wild-type microvessels
may involve inhibition of the basal Epac1-dependent activity.
Keywords atrial natriuretic peptide, cAMP, endothelial junction, Epac
deletion (mouse), microvascular permeability (in vivo), Rapgef.
The primary aim of the study was to investigate
whether the cAMP-stimulated Rap activator Epac
contributes to the tonic control of microvessel base-
line permeability in major organs of the mouse. The
well-recognized endothelial permeability lowering
effect of cAMP was first thought to be mediated by
cAMP-dependent protein kinase (PKA) only, but the
likely involvement of Epac was demonstrated using
Epac-activating cAMP analogues (Christensen et al.,
2003) that lowered the permeability of monolayers of
human embryonic vascular endothelial cells and atten-
uated the response to inflammatory conditions such
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as exposure to thrombin (Cullere et al. 2005). A role
of Epac1 and its target, the small GTPase Rap, to
modulate inflammation-associated endothelial hyper-
permeability has been confirmed in numerous in vitro
studies and noted in some in situ perfusion studies of
accessible microvessels, although the relative roles of
PKA, cGMP-dependent protein kinase (PKG) and
Epac in different organ vascular beds and under dif-
ferent experimental conditions still remain uncertain
(for recent reviews, see Spindler et al. 2010, Surapi-
sitchat & Beavo 2011, Kuhn 2012, Curry & Adam-
son 2013).
The role of Epac to maintain stable baseline perme-
ability in intact microvessels under non-inflammatory
conditions is less well studied. A major reason is the
lack of ways to reliably inhibit Epac and other cAMP-
dependent pathways pharmacologically in vivo (Spind-
ler & Waschke 2011), in part due to rapid metabolism
and renal clearance of cAMP analogues used to modu-
late Epac and PKA activity (Kleppe et al. 2015).
In this study, Epac-deficient mice (Epac1/ or
Epac2/) were generated to elucidate the potential
in vivo role of Epac in regulation of baseline macro-
molecule flux across microvascular endothelium.
Others have reported that Epac1/ and Epac2/ mice
have only subtle phenotypes. Epac2/ mice have a
slightly perturbed pathway of pancreatic beta cell insu-
lin exocytosis (Shibasaki et al. 2007), while Epac1/
mice have been reported to gain slightly more (Kai et al.
2013) or slightly less (Yan et al. 2013) body weight on
both low- and high-fat diets, and be less susceptible to
rickettsial invasion (Gong et al. 2013).
We report here an increased basal microvascular
transvascular albumin flux in skin, skeletal muscle and
intestines of Epac1/, but not Epac2/ mice.
Dynamic contrast-enhanced magnetic resonance imag-
ing (DCE-MRI) studies of the masseter muscle using
Gadomer-17 demonstrated transvascular flux of the
high molecular weight MR contrast agent, which con-
firmed that Epac1/ mice had constitutively increased
microvascular permeability to macromolecules. Trans-
mission electron microscopy was used to compare the
ultrastructure of the endothelial junctions in masseter
muscle biopsies from basal state in Wt and Epac1/
mice. They revealed decrease of junctional complex in
the interendothelial slits from Epac1/ mice.
To evaluate further whether Epac1 and/or Epac2
contributed to the regulation of vascular permeability
under physiological conditions, we tested the response
of microvessels to the naturally circulating atrial natri-
uretic peptide (ANP) in Wt, Epac1/ and Epac2/mice.
ANP is released when plasma volume is expanded and
increases vascular permeability to albumin as part of
the normal control of plasma volume. We and others
have demonstrated this action in Wt mice (Curry
et al. 2010, Lin et al. 2011), and also shown that it is
attenuated when cAMP is elevated, and proposed that
ANP might increase permeability via decreased Epac
activity (Lin et al. 2011). We show here that Epac1-
deficient mice, but not Epac2-deficient mice have an
attenuated response to ANP.
Materials and methods
Ethical approval
The animal experiments were approved by the Norwe-
gian Animal Research Authority and conducted accord-
ing to the European Convention for the Protection of
Vertebrates Used for Scientific Purposes, Norway.
Materials
The anti-Epac1 antibody was kindly provided by
J. Bos, University of Utrecht, the Netherlands. The
anti-Epac2 antibody (5B1) was from Cell Signaling
technology (www.cellsignal.com). The anti-CD31 anti-
body (DIA-310) was from Dianova, Hamburg, Ger-
many. ANP and rolipram were from Sigma-Aldrich
(St. Louis, MO, USA). Gadomer-17 was from in vivo
Contrast GmbH, Schering Pharma (Berlin, Germany).
Human serum albumin (HSA) was labelled with 131I
or 125I (from Perkin Elmer, Waltham, MA, USA) by
the iodogen method, as previously described (Curry
et al. 2010). Any free iodide was removed by spinning
twice on a 3-kDa cut-off column (Microcon filter;
Millipore, Bedford, MA, USA) prior to experiments.
The labelled HSA eluted like native HSA upon anionic
exchange and high-resolution size exclusion chro-
matography with online gamma radiation detection in
series with UV detector. Low molecular weight
radioactivity accounted for <0.3% of the total activity.
Generation of Epac1/ and Epac2/ knock-out
models. Epac1/ and Epac2/ mice were generated
by genomic deletion of exons 7–10 in Rapgef3 (encod-
ing Epac1) and exons 12–13 of Rapgef4 (encoding
Epac2) encoding the cAMP-binding domains of both
proteins (Fig. 1a,d) by use of the Cre–LoxP system. An
additional frame shift codon was introduced in exon
11 in Rapgef3 resulting in a stop codon at the start of
exon 11 (Fig. 1a). Heterozygous floxed Rapgef3 and
Rapgef4 mice were generated at the Mouse Clinical
Institute, Strasbourg, France, and subsequently crossed
with C57BL/6J mice expressing CRE recombinase
from the CMV promoter resulting in global deletion of
Epac1 and Epac 2 expression, as confirmed by
immunoblotting and RT-PCR (Fig. 1b,c,e). C57BL/
6JBomTac mice from Taconic, Denmark, were used to
backcross the recombined chimeric mice for at least 10
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generations. The origin of the C57BL/6JBomTac mice
is described at http://www.taconic.com/wmspage.cfm?
parm1=764.
Genotyping
For genotyping, DNA was extracted from one
1.5-mm-diameter ear punch according to Truett et al.
(2000). The deletion of exon 7–10 in Epac1/and exon
12–13 in Epac2/ was confirmed by PCR (Qiagen,
Hilden, Germany; Multiplex PCR Kit, Cat.No:
206143) using primers P1–P3 and P4–P6 respectively.
P1, CAC-AGA-CAG-TGC-TTA-GCA-CAG-TGC; P2,
CAC-CTC-TCT-TCC-CAA-ACC-TAG-AGC-C; P3,
GCC-CCA-AGG-CTG-CTG-ATC-CC; P4, TGA-AT
T-ATG-GGG-GAA-CGC-ACT-TTC-C; P5, GTG-TGG
Figure 1 Generation of the Epac1/ and Epac2/ mouse strains. (a) The Epac1 (Rapgef3) gene targeting construct and dele-
tion strategy. (b) Anti-Epac1 immunoblots showing lack of Epac1 protein in Epac1/ mouse tissue and decreased expression in
Epac1/+ compared to Wt tissue. (c) PCR genotyping demonstrates the sizes of PCR products predicted for the Epac1 deletion
(see Methods for details; WAT is white adipose tissue). (d) The Epac2 (Rapgef4) gene targeting construct and the deletion strat-
egy. The deletion includes the functional cAMP-binding domain common for all known Epac2 isoforms. (e) Anti-Epac2 immu-
noblots showing lack of Epac2 protein in Epac2/ mouse organs (brain, adrenal cortex) with high expression of Epac2. (f)
PCR genotyping validation of the deletion.
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-TGC-TAT-GAA-ATT-GGT-TCC-GTT-G; P6, TGC-C
TC-CAT-TGT-TCT-TCG-GG.
The PCR was for 30 cycles of 94 °C (each 30 s),
63 °C (Epac1) or 60 °C (Epac2) for 90 s, 72 °C for
90 s, and finally 72 °C for 10 min. For Epac1, the pre-
dicted size of the <1000 bp PCR product is 525 bp for
Wt and 315 bp for Epac1/ tissue (P1–P3). For Epac2,
it is 495 bp for Wt and 332 for Epac2/ tissue (P4–P6).
Immuno (Western) blotting
Immunoblotting was performed essentially as descri-
bed elsewhere (Gausdal et al. 2004). The membra-
nes were probed with either mouse monoclonal
anti-Epac1 or mouse monoclonal anti-Epac2. Bands
representing the proteins of interest were detected
using alkaline phosphatase-conjugated secondary anti-
bodies and CDP-Star substrate (Tropix, Bedford,
MA, USA) and band intensity determined in a Fuji
LAS3000 (Fuji Photo Film, Tokyo, Japan).
Animal experiments
General. Artificial lighting was maintained on a
12 : 12-h light–dark cycle. Room temperature was
kept constant at 23 °C, and the animals were provided
with water and rodent chow ad libitum. The mice were
12–16 weeks old when used for experiments, the ratio
of female to male mice being about one (0.8–1.2). The
weight range was 20–25 g for the female and 25–30 g
for the male mice. All experimental procedures were
performed while animals were anesthetized using 3.5%
isoflurane (Isoba vet; Schering-Plough Animal Health,
Uxbridge, UK) and maintained with 1.5–2% isoflurane
in air. The anaesthesia was supplied via a nose cone.
During anaesthesia, the body temperature, and in the
case of MRI, also the respiration rate was monitored
continuously and kept stable during the experiments. A
single catheter was placed in a tail vein (MRI) or the
jugular vein (two-tracer method) for infusions.
Determination of arterial blood pressure. Arterial
blood pressure (BP) was measured in five Epac1/
and six wild-type mice by the tail-cuff method follow-
ing the instructions of the manufacturer (CODA5;
Kent Scientific, Torrington, CT, USA). Briefly, the
mice were pre-warmed in an incubator at 32 °C for
30–45 min and then transferred to a tube for measur-
ing the BP. The tubes were placed on a heating pad to
keep the mice warm. The warming prevents tail vessel
vasoconstriction and ensures optimal vasodilation for
the blood pressure determination. Measurement of
blood pressure was performed in five cycles, each
20 s. Each mouse was trained on day 1, and the blood
pressure measured each of the two following days.
Determination plasma albumin and total protein con-
centration. Blood (20 lL) from the facial vein of live
mice was drawn into syringes coated with acid–
citrate–dextrose solution. The blood was centrifuged
at 150 g for 4 min, and the resulting platelet-rich
plasma centrifuged at 1000 g for another 5 min. The
plasma concentration of albumin and total plasma
protein was compared in Wt and Epac/ mice using
a label-free proteomic method as described elsewhere
(Haslene-Hox et al. 2011).
The two-tracer method for determination of intact
mouse tissue albumin clearance
The two-tracer method (Curry et al. 2010) was used to
determine albumin clearance. The method depends on
the sequential infusion of 125I-HSA and 131I-HSA. It
has been validated for determination of albumin leak-
age in Wt mice and explained in detail in (Curry et al.
2010). In brief, 125I-HSA (0.1 MBq) was given i.v. over
30 s in 0.05 mL of saline. Thirty minutes thereafter,
131I-HSA (0.05 MBq) was injected (also i.v. in
0.05 mL of saline over 30 s). Five minutes thereafter,
cardiac blood was withdrawn for plasma sampling,
and the mice were killed by i.v. injection of saturated
KCl. Tissue samples were rapidly dissected from back
skin (four samples: left and right upper and lower
quadrant), skeletal muscle (quadriceps), heart, small
intestine (jejunum), large intestine (colon) and adipose
tissue (inguinal white fat). The tissues and plasma sam-
ples were transferred to pre-weighed vials, which were
sealed and immediately reweighed. After determination
of radioactivity, the tissue samples were de-sealed and
evaporated in a drying chamber at 60 °C. The vials
were weighed repeatedly until stable weight (normally
after 2–3 weeks) was reached. The radioactivity was
determined in a gamma-counting system (LKB Wallac
1285, Turku, Finland). Spillover from 131I to 125I was
corrected automatically. Blood-to-tissue clearance was
estimated as the extravascular plasma equivalent vol-
ume of 125I-HSA (counts min1 per g dry tissue
weight)/(counts min1 per mL plasma). The clearance
over 30 min is the difference between the plasma
equivalent distribution volume of 125I-HSA at 35 min
and that of 131I-HSA at 5 min. All clearances were ref-
erenced to tissue dry weight. The clearance data were
also normalized to clearance per unit blood volume by
dividing clearance by the plasma volume in the sample
to minimize effects of variable blood filling between the
samples (see Curry & Adamson 2010 for discussion).
DCE-MRI to determine Gadomer-17 microvascular
clearance. Dynamic contrast-enhanced magnetic reso-
nance imaging was performed to determine the clear-
ance of macromolecular tracers. The MR contrast
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agent Gadomer-17 has a molecular weight of 17 kDa,
but due to its dendrimeric structure, its Stokes radius
is as for globular proteins of molecular weight
35 kDa (Misselwitz et al. 2001). The contrast agent
was injected over 15 s during scanning through a
catheter in the tail vein after acquisition of 30 baseline
images. For the ANP study, 0.4 mmol Gadomer kg1
(diluted 1 : 4 in saline) was injected. In the rolipram
study, 0.2 mmol Gadomer kg1 was injected. The
MRI was performed using a horizontal bore 7T small
animal MRI instrument (PharmaScan; Bruker Corpo-
ration, Ettlingen, Germany), equipped with dedicated
mouse bed and head coil. DCE-MRI data were
obtained with a T1-weighted FLASH sequence (Fast
Low Angle Shot) with a flip angle of 25°, repetition
time and echo time of 13.77 and 2.52 ms respectively.
A total of 600–1200 axial images through the mas-
seter muscle were acquired with a sampling interval of
0.99 s, with a slice thickness of 1 mm, field of view of
2.5 cm and acquisition matrix of 96 9 96.
A separate group of animals (n = 9) was used to
determine the signal over time in large supplying ves-
sels to the head to estimate the arterial input function
(AIF). An oblique sagittal slice was positioned over
the carotid arteries, and 1200 T1-weighted (same
acquisition parameters as above) with a sampling
interval of 0.99 s were acquired. The signal intensity
over time was acquired in a region of interest of the
internal masseter muscle using Nordic Image Control
and Evaluation (nICE; Nordic Imaging Lab AS, Ber-
gen, Norway). The data were further processed using
MATLAB (The Mathworks, Natick, MA, USA) to imple-
ment the step/slope model as previously described
(Curry et al. 2010). The rate constant (0.0063 s1)
for Gadomer-17 was equal for all animals based on
the estimation of the AIF above. The rate constants
were estimated using blind deconvolution as previ-
ously described (Taxt et al. 2012).
Investigation of the effect of ANP and rolipram on
Gadomer-17 clearance—Three series of experiments
were performed. In the first series, 20 Epac1/ and 20
Wt mice were used. Ten mice in each group received
ANP and 10 received vehicle (PBS without potassium).
ANP (500 ng (kg BW)1 min1) or vehicle was given
as a 30 min continuous infusion before the Gadomer-
17 injection. The DCE-MRI experiments were per-
formed as described above. In the second series, 20
Epac2/ and 20 Wt mice were used. Again, 10 mice
in each group received ANP and 10 received vehicle.
Finally, for the rolipram study, 20 Epac1/ and 20 Wt
mice were used. Ten of the mice in each group received
8 mg kg1 BW rolipram intraperitoneally and 10
received vehicle just before the Gadomer-17 injection
and start of MR image acquisition.
Investigation of the effect of ANP on albumin cleara-
nce—Atrial natriuretic peptide (500 ng (kg BW)1 min1)
or vehicle was given as a continuous infusion for
30 min directly after the initial 125I-HSA injection (as
described above) to either 20 Epac1/ or 20 Wt mice.
Transmission electron microscopy. Tissue was dis-
sected from the mice immediately after euthanasia,
sliced into 1 mm3 cubes, fixed for 24 h in 1.5% glu-
taraldehyde in 0.1 M Na-cacodylate buffer (pH 7.4) and
post-fixed in 1% osmium tetroxide (OsO4) for 60 min.
Dehydration was in graded alcohol solutions. After
embedding in Agar 100 resin, ultra-thin sections were
cut and stained with uranyl acetate and lead citrate. Sec-
tions were examined in a Jeol (Tokyo, Japan) JEM-1230
electron microscope. The sections were cut perpendicu-
lar to the long axis of the muscle fibres and their accom-
panying microvessels. The transverse microvessel
sections were scrutinized for presence of endothelial slits
(junctions), which were counted. High-magnification
digital micrographs of the junctions were analysed on a
screen for the presence and length of dense junctional
complexes. In addition, the slit length (including any
curvatures) and calibre (the interendothelial cell distance
not obstructed by electron-dense material) was deter-
mined.
Immunohistochemical staining of endothelial CD31,
estimation of capillary density. Sections (4 lm thick)
of paraffin-embedded masseter muscle were dewaxed,
microwave-treated with 10 mM citric acid, pH 6.0 and
subsequently blocked for 10 min at 25 °C with 5%
BSA and 5% normal rabbit serum in 0.05 M Tris, pH
7.4, 0.15 M NaCl (TBS) before being immunostained
for 18 h with anti-CD31 antibody (1 : 20 in TBS with
1% BSA) at 4 °C. The sections were next treated with
3% H2O2 in PBS for 5 min before incubation with bio-
tin-labelled secondary antibody (Biotinylated anti-rat
IgG; Vector BA-4001) for 45 min. The immunohisto-
chemical reactions were developed using the ABC Vec-
tastain Elite staining kit (Vector Laboratories,
Burlingame, CA, USA), based on avidin-coupled perox-
idase. The sections were counterstained with haema-
toxylin. The number of capillaries per fibre was
estimated based on counting 300–550 capillaries from
13 photographs of random sections from two Wt and
two Epac1/ mice.
Statistical methods
Differences between groups were tested with one-way
ANOVA with subsequent post hoc testing using GRAPHPAD
INSTAT (GraphPad Software, La Jolla, CA, USA). Two-
tailed t-tests were used when comparing only two
groups. When testing ANP-effects, one-tailed testing
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was used as extensive studies by others and us have
failed to demonstrate any case when ANP decreases
endothelial permeability. The Mann–Whitney two-
tailed U-test (http://elegans.som.vcu.edu/~leon/stats/
utest.html) was used to assess whether endothelial slit
calibre or the magnitude of endothelial junctional com-
plex differed significantly between samples from Wt
and Epac1/ mice, as such data are not normally dis-
tributed. Values are generally given as mean  SEM.
Results
Verification of the Epac deletions
The Rapgef3 gene coding for Epac1 was silenced by a
deletion comprising the exon coding for the cAMP-
binding domain, removing the possibility of cAMP
regulation of any product of the disrupted Rapgef3
gene. The deletion introduced, in addition, a missense
mutation to avoid translation of the C-terminal part
active site containing part of the Epac1 molecule (see
Fig. 1a for details). Epac1 was not detected by Wes-
tern blot analysis in any tested tissue from the
Epac1/ mice. Compared with Wt mice, the expres-
sion was lower in Epac1+/ mice (Fig. 1b). The dele-
tion was confirmed by PCR of genomic DNA
(Fig. 1c).
A similar strategy (deletion of the functional cAMP-
binding domain) was used for Rapgef4 (Fig. 1d). The
Rapgef4 gene codes for 3 Epac2 size variants (a, b, c).
Each variant has a separate promoter, whose methyla-
tion state decides which size variant is expressed (Ueno
et al. 2001, Niimura et al. 2009, Hoivik et al. 2013).
As the functional cAMP-binding domain is common
for all size variants (Kawasaki et al. 1998, de Rooij
et al. 1998), Epac2A (highly expressed in brain;
Fig. 1e), Epac2B (highly expressed in adrenal cortex;
Fig. 1e) and Epac2C (highly expressed in the parenchy-
mal hepatocytes of the liver; not shown) were absent in
the Epac2/ mouse. PCR of genomic DNA confirmed
the deletion of Epac2 (Fig. 1f). The Epac1/ and
Epac2/ mice were able to reproduce and had normal
life span.
Arterial blood pressure
The Epac1/ mice have, like the Wt mice, normal
blood pressure. After 2 days of habituation to the pro-
cedure, the mean arterial pressure in Wt mice was
101  6.3 mmHg (systolic 122  6.6 and diastolic
98  6.4) against 102  4.9 mmHg (124  4.9 and
91  5.2) in Epac1/ mice. The first day after train-
ing, the mean pressure was slightly higher, but again
near identical in Wt (108  4.3) and Epac1/
(108  4.3) mice. We considered it therefore unlikely
that the basal state microvascular transendothelial flux
could differ in Wt and Epac1/ mice due to divergent
blood pressure.
Plasma albumin and total protein concentration
The albumin concentration and total plasma protein
concentration were similar in Wt and Epac1/ mice,
as determined by quantitative proteomic analysis (ar-
bitrary units). Serum albumin was 10.0  1.0 and
total protein 18.8  0.8 in Wt, against 10.0  0.2
and 17.8  1.4 in Epac1/ mice.
Epac1/ mice have constitutively increased
microvascular albumin permeability in major organs
The movement of albumin from the vascular to the
extravascular compartment was evaluated by the
two-tracer method. The experiments were executed in
two separate series (one for Epac1/ and one for
Epac2/), each with Wt animals as control. The two
Wt groups were tested against each other. As there was
no difference between them, a combined group consist-
ing of all Wt animals was used for comparison with the
Epac1/ and Epac2/ animals.
The local plasma volume of each tissue sample was
determined from the content of 131I-HSA, which was
infused 5 min before euthanasia, and was similar in
tissue samples from Wt, Epac1/ and Epac2/ ani-
mals (for details see legend to Fig. 2). The Epac1/
mice had significantly increased albumin clearance
(normalized to plasma volume) in skin, skeletal mus-
cle, adipose tissue and large intestine (Fig. 2). An
increase in albumin clearance when expressed relative
to local plasma volume is a strong indication of an
actual change in vascular permeability, as it compen-
sates for differences in surface area for exchange. In
contrast to Epac1/ mice, the Epac2/ mice had
albumin clearance similar to Wt mice in skin, skeletal
muscle, adipose tissue and large intestine, but was
increased in the small intestine (Fig. 2). Taken
together, these results indicate that Epac1, but not
Epac2, provided a significant contribution to the basal
macromolecular endothelial permeability in most of
the organs studied here.
The microvascular clearance of the MRI contrast agent
Gadomer-17 is enhanced in the masseter muscle of
Epac1/ mice
To obtain further evidence for a role of Epac1 in
macromolecule endothelial permeability and eliminate
the (unlikely) possibility that increased albumin clear-
ances were due to an albumin-specific uptake mecha-
nism, additional studies were performed using the
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synthetic macromolecule Gadomer-17 in the immobi-
lized M. masseter skeletal muscle of Wt and Epac1/
mice. The initial rapid rise of the MRI signal after
intravenous Gadomer-17 injection seen in Figure 3a
reflected blood vessel filling and was similar for Wt
and Epac1/ animals, suggesting near-identical vascu-
lar volumes. Thereafter, the MR signal intensity
became higher in muscle from Epac1/ mice than Wt
mice, indicating increased constitutive permeability in
Epac1/ microvasculature. Apparently, the loss of
Epac1 affected a pathway for microvascular macro-
molecule exchange common for albumin and Gado-
mer-17 (Fig. 3b). We finally tested whether lack of
Epac1 also could blunt the known permeability
decreasing effect of the cAMP elevating PDE4 inhibi-
tor rolipram in the masseter muscle (Lin et al. 2011).
Rolipram induced a lowering of Gadomer-17 perme-
ability that was blunted in Epac1/ masseter
Figure 2 The normalized albumin clearance is increased in skin, skeletal muscle, adipose tissue and large intestine of Epac1/,
but not Epac2/ mice. The normalized clearance (NC) in tissue samples of back skin, skeletal muscle, white adipose tissue,
small and large intestine, and heart is shown mL g1 dry weight (average  SEM). The NC is the ratio of the clearance (based
on relative tissue sample content of 125I-HSA infused 35 min before euthanasia) and the local tissue plasma volume (relative
content of 131I-HSA, infused 5 min before euthanasia). P-values < 0.05 (*) and <0.001 () are shown. The plasma volume
(mL g1 dry weight) was, with the exception of jejunum from the Epac2/ mice, similar between Wt (n = 19), Epac1/
(n = 9) and Epac2/ (n = 9) mouse tissues: Skin: Wt: 0.023  0.002, Epac1/: 0.020  0.002, Epac2/: 0.027  0.003;
quadriceps muscle (corresponding values): 0.022  0.003, 0.014  0.001, and 0.018  0.002; inguinal fat: 0.024  0.001,
0.023  0.002 and 0.028  0.003; jejunum: 0.101  0.008, 0.116  0.017 and 0.064  0.006; colon: 0.042  0.004,
0.033  0.002 and 0.032  0.003; heart: 0.229  0.013, 0.215  0.019, and 0.205  0.015. HSA, human serum albumin.
Figure 3 The constitutive Gadomer-17
clearance is increased in masseter muscle
of Epac1/ compared to Wt mice. (a)
Typical magnetic resonance imaging
(MRI) signal intensity (SI) obtained upon
continuous scanning of a masseter region
from Epac1/ (red) or Wt (green)
mouse before and after Gadomer (Gd)-
17 injection. The solid lines show fits
based on the calculated permeability
coefficient. (b) The Gd 17 permeability
coefficient calculated from the scanning
data obtained before and after infusion
of vehicle or rolipram, each animal serv-
ing as its own control. P-values < 0.05
are shown (n = 10). (c–e) The endothe-
lium of transverse sections of M. mas-
seter from Epac1/ (c) or Wt (e) mice
was visualized by anti-CD31 staining
and the capillary/myofibre ratio deter-
mined (d). Error bars are SEM.
P-values < 0.05 (*) are shown.
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(Fig. 3b). The results could not be explained by
decreased microvascularity in the Epac1/ masseter
as its capillary density was similar to Wt masseter
(Fig. 3c–e). We conclude that Epac1/ masseter has
increased microvascular permeability both under basal
and rolipram-stimulated conditions.
Comparison of the microvascular permeability enhancing
effect of ANP in Wt and Epac1/ mice
We and others have previously demonstrated that
ANP increases the baseline microvascular permeability
of Wt mice, particularly in skin and muscle (therefore,
one-tailed t-testing was used). It is not known whether
ANP acts through Epac1 inhibition or independently
of Epac1. We reasoned that if ANP acted indepen-
dently of Epac or an Epac-induced pathway, it should
enhance permeability to the same level in Wt and
Epac1/ mice. We failed to note any further ANP-
induced increase of permeability in the Epac1/ mice
(Fig. 4a,b), unlike in the Epac2/ mice (Fig. 4c).
Besides, the albumin permeability enhancing effect of
ANP was, if anything, slightly lower in magnitude
than the effect of deleting Epac1 (Fig. 4a). The above
results are consistent with an action of ANP to reduce
the effectiveness of an Epac1 pathway to maintain the
constitutive vascular permeability.
A possible consequence of constitutively increased
loss of albumin from the vascular to the extravascular
compartment could be a slight increase of interstitial
oncotic pressure accompanied by a slight water accu-
mulation. As the tissue samples to be analysed for
albumin isotope content were weighed before and
after drying (see the Experimental section for details),
we could compare their water content (relative to dry
weight). Only in skin was the water content high
enough to produce experimentally reliable data.
Epac1/ back skin had about 2% higher water con-
tent than back skin from Wt mice (Fig. 5). Further,
the magnitude of the increase in water content was
similar whether or not they were treated with ANP.
This is not unexpected due to the short exposure time
to ANP and the modest albumin permeability rate of
back skin under the experimental conditions. In con-
trast, the Epac1/ mice have a constitutive opportu-
nity to retain fluid subsequent to the increased
albumin permeability.
Epac1/ microvessels have structurally less constricted
interendothelial slits
We next studied whether the different Gadomer-17
permeability observed between Wt and Epac1/ mas-
seter muscle had structural microvascular correlates.
Figure 4 The effect of atrial natriuretic peptide (ANP) on macromolecule microvascular permeability in tissue from Wt,
Epac1/ and Epac2/ mice. (a) The effect of ANP on the normalized albumin clearance is shown for tissues from Wt and
Epac1/ mice. The mice were given vehicle or ANP 30 minutes before euthanasia, and the apparent plasma volume and albu-
min clearance determined by the [131I]albumin/[125I]albumin method as for the experiment shown in Figure 2. (b) The effect of
ANP on the microvascular permeability of Gadomer-17 is shown for masseter muscle from Wt and Epac1/ mice. (c) The
effect of ANP on the normalized albumin clearance for tissues from Wt and Epac2/ mice. Error bars are SEM (n = 10). P-
values < 0.05 (*) and <0.01 (+) are shown.
© 2016 The Authors. Acta Physiologica published by John Wiley & Sons Ltd on behalf of
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As already noted, the microvessel density did not
differ between Epac1/ and Wt masseter muscle
(Fig. 3c–e). We therefore investigated transverse
sections of Epac1/ masseter muscle microvessels
by electron microscopy for differences at the ultra-
structural level. These analyses revealed a trend
towards shorter and wider junctions in Epac1/ cap-
illaries (average length and width were 395 and
13 nm in Epac1/ against 483 and 11 in Wt;
P > 0.05). More importantly, a highly significant
difference existed between Wt and Epac1/ endothe-
lial slits regarding the extent and density of junctional
complex material. On average, Wt clefts had 224 nm
of strongly developed junctional complex against only
97 nm for Epac1/ clefts (Fig. 6a). Four of the 48 slit
sections scrutinized from Epac1/ microvessels had
no constrictions <6 nm and no areas with strong accu-
mulation of junctional complex material, against only
one for the 57 studied slits from Wt mice. The most
extreme examples of slit difference in distribution of
electron-dense material are shown in Figure 6b–e.
These observations demonstrated ultrastructural dif-
ferences between endothelial slits from Wt and
Epac1/ animals under basal conditions, consistent
with the finding that macromolecules such as Gado-
mer-17 and albumin have increased capillary perme-
ability in Epac1/ compared with Wt tissues.
Discussion
The present study demonstrates increased albumin
clearance in several tissues of Epac1/ mice under
basal in vivo conditions. The Epac1/ animals have
normal plasma protein levels, normal blood pressure,
and similar microvessel density and initial tissue blood
filling of injected labelled albumin or Gadomer-17 as
Wt animals. Enhanced transendothelial vesicle trans-
port of surface receptor bound albumin has been
described in some ANP-stimulated specialized
endothelia (Chen et al. 2012), but is unlikely to
(a)
(b) (c)
(d) (e)
Figure 6 The endothelial junctional density of Epac1/ and Wt capillaries. (a) The average length of each endothelial slit
found associated with strong junctional complex (JC) in Wt and Epac1/ M. masseter. Error bars are SEM. The P-value for
the difference between Epac1/ and Wt slits was <0.00002 by the Mann–Whitney two-tailed U-test and <0.0003 by the two-
tailed t-test. (b–e) Examples of junctions from Wt and Epac1/ mice. The two Wt junctions shown (b, c) had more abundant
JC than found in any of the 48 Epac1/ junctions studied. The two Epac1/ junctions shown (d, e) had less abundant JC than
any of 57 Wt junctions studied.
Figure 5 The water content of back skin from Wt and
Epac1/ mice. The water content (mL g1 dry weight) of
back skin from Epac1/ mice and Wt mice injected with
vehicle or atrial natriuretic peptide (ANP) was determined in
the tissue samples used for the experiments on albumin clear-
ance shown in Figures 2 and 4a, as described in the experi-
mental section. Error bars are SEM (n = 10). P-value < 0.05
(*) is shown.
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explain the enhanced albumin clearance of Epac1/
animals as they had increased clearance also of the
artificial macromolecule Gadomer-17. Our results
therefore conform to the hypothesis that tonic activity
of Epac1-dependent pathways contributes to the main-
tenance of baseline vascular permeability, and loss of
this activity leads to a sustained increase in baseline
permeability. We ascribe this phenotype to enhanced
permeability of the interendothelial junctions of
Epac1/ mouse microvessels.
A number of studies implicate PKA alone or PKA
and Epac together as responsible for cAMP-induced
endothelial barrier tightening (Rampersad et al. 2010,
Surapisitchat & Beavo 2011, Curry & Adamson 2013).
The present study does not exclude an action of PKA in
maintaining the endothelial barrier in vivo, but suggests
that Epac1 has a dominant role compared to PKA in
intact microvessels as treatment with rolipram, which
would increase cAMP and PKA activity, failed to over-
come the lack of Epac1 (Fig. 3). A similar dominant
role of Epac1 was noted in arterial endothelial cells
in vitro, where the junctional protein VE-cadherin colo-
calizes with PKA, a PDE4D/Epac1 complex, and the
Epac target Rap1 in a ‘signalosome’ controlling the
paracellular permeability (Rampersad et al. 2010). It is
noted that these conclusions apply principally to the sit-
uation where the molecular complexes regulating
cAMP are tethered close to the cell membrane. The
tethering of PKA, Epac1 and their substrates close to
sites of production of cAMP or cGMP and members of
the cyclic nucleotide phoshodiesterase (PDE) family of
cyclic nucleotide degrading enzymes is an important
part of the regulatory scheme (Maurice 2011). Thus,
lung endothelial cells responded to cAMP produced by
a soluble bacterial adenylyl cyclase by interendothelial
cell gap formation, facilitating bacterial invasion and
oedema formation. The same cells showed restricted
permeability, however, when cAMP was produced
close to the surface membrane. In either case, the cAMP
effect was attributed to PKA activation (Prasain et al.
2009, Ochoa et al. 2012).
Our observations provide new insight into mecha-
nisms that regulate vascular permeability. In particu-
lar, they imply that Epac1 activity exerts a tonic
inhibition of microvessel permeability. One potential
way to relieve the Epac1-dependent inhibition in the
intact animal is by lowering the cAMP concentration
close to the endothelial junction. In fact, this has been
proposed as explanation for the ANP-enhanced
microvessel permeability. The ability of ANP to
enhance microvascular albumin clearance depends on
its binding to the endothelial cGMP producing recep-
tor GC-A (Kuhn et al. 2009, Kuhn 2012). The result-
ing cGMP increase can (i) directly activate PKG, (ii)
directly inhibit PDE3 degradation of cAMP and thus
indirectly activate PKA and Epac, or (iii) directly acti-
vate PDE2 to indirectly lower cAMP and thereby
reduce PKA and Epac activity (Surapisitchat et al.
2007, Birukova et al. 2008, Kuhn 2012). Epac1 does
not bind cGMP at physiologically relevant concentra-
tions (Christensen et al. 2003), but as in (iii) above, a
cGMP burst can inhibit Epac indirectly by stimulating
PDE2 to degrade cAMP in an endothelial cell com-
partment close to Epac1 (Kraynik et al. 2013). This
scenario is compatible with the present findings as the
ANP effect was blunted or absent in the Epac1/ ani-
mals (Fig. 4a) and that rolipram, a strong inhibitor of
the cAMP-specific PDE4, easily overrides ANP-
induced hyperpermeability in vivo (Lin et al. 2011).
Such overriding is less easily explained for purely
cGMP-regulated putative ANP mediators like PKG
(Schreier et al. 2008). Besides, the constitutive
endothelial barrier resistance was lowered to at least a
similar extent by Epac1 deficiency compared to expo-
sure to ANP, as expected if ANP acted to inhibit
Epac1 through a moderate decrease of endothelial cell
cAMP (Kraynik et al. 2013).
As our animal models had global Epac deletion, the
observed endothelial phenotype might in part be
caused by deletion of Epac1 in non-endothelial cells.
We considered therefore whether it could be related to
constitutively increased aldosterone output from the
adrenal cortex, where ANP decreases aldosterone pro-
duction through GC-A/cGMP/PDE2-dependent lower-
ing of cAMP (Tsai & Beavo 2011). This is unlikely
because the adrenocortical cells express Epac2 rather
than Epac1 (Niimura et al. 2009, Hoivik et al. 2013,
see also Fig. 1e), and our Epac2/ animals responded
fully to ANP (Fig. 4c). Secondly, the ANP effect on
microvascular permeability is abolished in mice with
endothelial-specific deletion of the GC-A receptor for
ANP (Curry et al. 2010). Thirdly, our Epac mice had
normal blood pressure, arguing that their renin–an-
giotensin–aldosterone axis was unperturbed. The pre-
sent study supports therefore the notion that ANP may
modulate endothelial permeability in vivo through
lowering the cAMP concentration near Epac1.
The ultrastructural analysis of the junctions between
endothelial microvessel cells demonstrated less elec-
tron-dense junction complex material in Epac1/ than
in Wt microvessels (Fig. 6). Thus, it is likely that
microvessels in Epac1/ mice have more discontinu-
ities in the band of tight junction material that effec-
tively seals the junctions to molecules the size of
albumin and Gadomer-17. The effect of such disconti-
nuities on permeability depends on their three-dimen-
sional arrangement (Weinbaum & Curry 1995, Michel
& Curry 1999). Assuming a similar arrangement in wt
and Epac1/ mice, our results are consistent with a
hyperpermeable state. The present study does not
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address whether the paucity of junction material in
Epac1/ slits is readily reversible, but it may be noted
that the forskolin/rolipram-induced endothelial barrier
tightening of rat mesenteric post-capillary venules
occurs rapidly in vivo (Spindler et al. 2011).
An important question is the role of Epac1-depen-
dent pathways in relation to other signal mediators,
such as sphingosine-1 phosphate (S1P) that also exerts
a tonic control of vascular permeability (Curry &
Adamson 2013). As it is reasonable to assume that
S1P was present at normal levels in our experiments,
we conclude that reduced Epac1 activity can increase
permeability at physiological levels of S1P.
Our observations have potentially useful transla-
tional implications. Agents selectively targeting Epac1
may be sufficient and more precise tools than general
cAMP agonists to modulate the endothelial barrier
in vivo. Cyclic nucleotide analogues, including those
with potential as Epac1 modulators, so far have not
been useful in intact mammals, mainly because they,
like cAMP itself, are rapidly cleared through active
renal excretion and metabolism by phosphodiesterases
(for recent review see Kleppe et al. 2015). New inhibi-
tors of Epac that act outside the cyclic nucleotide bind-
ing site have been produced. So far, they are specific for
Epac2 (Tsalkova et al. 2012, Chen et al. 2013), which
appears not to be involved in the control of the endothe-
lial barrier. Nevertheless, this new inhibitor class indi-
cates a route to produce modulators of Epac1, which
may become useful to control the endothelial barrier.
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